Price (delayed)
$28.11
Market cap
$16.68B
P/E Ratio
18.62
Dividend/share
$0.83
EPS
$1.51
Enterprise value
$22.52B
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals
Highlights
The P/E is 63% lower than the 5-year quarterly average of 50.6 and 35% lower than the last 4 quarters average of 28.8
Royalty Pharma's EPS has surged by 175% YoY but it has decreased by 16% QoQ
The net income has soared by 164% YoY but it has contracted by 16% from the previous quarter
The company's quick ratio fell by 25% QoQ
Royalty Pharma's debt has increased by 24% QoQ and by 7% YoY
Key stats
What are the main financial stats of RPRX
Market
Valuations
Earnings
Shares outstanding
593.46M
Market cap
$16.68B
Enterprise value
$22.52B
Price to earnings (P/E)
18.62
Price to book (P/B)
1.72
Price to sales (P/S)
5.67
EV/EBIT
26.19
EV/EBITDA
26.19
EV/Sales
10.06
Revenue
$2.24B
EBIT
$859.77M
EBITDA
$859.77M
Free cash flow
$2.62B
Per share
Balance sheet
Liquidity
EPS
$1.51
Free cash flow per share
$5.81
Book value per share
$16.32
Revenue per share
$4.96
TBVPS
$39.15
Total assets
$17.66B
Total liabilities
$7.9B
Debt
$7.6B
Equity
$9.75B
Working capital
$2.3B
Debt to equity
0.78
Current ratio
9.35
Quick ratio
9.35
Net debt/EBITDA
6.79
Margins
Efficiency
Dividend
EBITDA margin
38.4%
Gross margin
100%
Net margin
30.1%
Operating margin
42.9%
Return on assets
4.1%
Return on equity
6.9%
Return on invested capital
3.9%
Return on capital employed
4.9%
Return on sales
38.4%
Dividend yield
2.95%
DPS
$0.83
Payout ratio
55%
RPRX stock price
How has the Royalty Pharma stock price performed over time
Intraday
-2.06%
1 week
-3.17%
1 month
7.04%
1 year
-3.7%
YTD
0.07%
QTD
6.6%
Financial performance
How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.24B
Gross profit
$2.24B
Operating income
$960.19M
Net income
$673.24M
Gross margin
100%
Net margin
30.1%
Royalty Pharma's net margin has surged by 179% YoY but it has decreased by 16% QoQ
The net income has soared by 164% YoY but it has contracted by 16% from the previous quarter
The operating margin has surged by 132% year-on-year and by 2.1% since the previous quarter
The operating income has soared by 120% YoY and by 2.2% from the previous quarter
Growth
What is Royalty Pharma's growth rate over time
Valuation
What is Royalty Pharma stock price valuation
P/E
18.62
P/B
1.72
P/S
5.67
EV/EBIT
26.19
EV/EBITDA
26.19
EV/Sales
10.06
Royalty Pharma's EPS has surged by 175% YoY but it has decreased by 16% QoQ
The P/E is 63% lower than the 5-year quarterly average of 50.6 and 35% lower than the last 4 quarters average of 28.8
RPRX's P/B is 36% below its 5-year quarterly average of 2.7
The P/S is 20% below the 5-year quarterly average of 7.1 but 3.1% above the last 4 quarters average of 5.5
The revenue has decreased by 5% YoY
Efficiency
How efficient is Royalty Pharma business performance
The ROA has soared by 173% YoY but it has decreased by 16% from the previous quarter
RPRX's ROE has soared by 165% YoY but it is down by 15% from the previous quarter
Royalty Pharma's return on sales has surged by 104% YoY but it has decreased by 13% QoQ
The ROIC has soared by 86% YoY but it is down by 15% QoQ
Dividends
What is RPRX's dividend history
DPS
$0.83
Dividend yield
2.95%
Payout ratio
55%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 123% more than its total liabilities
The total liabilities has increased by 26% since the previous quarter and by 8% year-on-year
The current ratio has declined by 25% since the previous quarter
Royalty Pharma's debt is 22% lower than its equity
The debt to equity has increased by 26% QoQ and by 7% YoY
Royalty Pharma's debt has increased by 24% QoQ and by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.